Bionano Genomics, Inc. (NASDAQ:BNGO) Stock Short Interest Report for September

Bionano Genomics, Inc. (NASDAQ:BNGO) saw a significant increase in short interest during the month of September. As of September 30th, there was short interest totaling 2,035,020 shares, an increase of 77.9% from the September 15th total of 1,144,194 shares. Approximately 17.4% of the shares of the company are sold short. Based on an average daily trading volume, of 978,648 shares, the days-to-cover ratio is presently 2.1 days.

Bionano Genomics Price Performance

NASDAQ BNGO traded down $0.12 during trading hours on Friday, reaching $1.25. The company’s stock had a trading volume of 181,139 shares, compared to its average volume of 469,257. The firm’s 50-day moving average price is $1.37 and its 200-day moving average price is $1.25. The company has a quick ratio of 1.96, a current ratio of 2.48 and a debt-to-equity ratio of 0.11. Bionano Genomics has a 1 year low of $1.00 and a 1 year high of $2.23. The company has a market capitalization of $14.72 million, a price-to-earnings ratio of -0.41 and a beta of 1.66.

Bionano Genomics (NASDAQ:BNGO) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.03. The business had revenue of ($6.67) million during the quarter, compared to the consensus estimate of $7.55 million. Bionano Genomics had a negative return on equity of 78.78% and a negative net margin of 106.58%. On average, equities research analysts predict that Bionano Genomics will post -2.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Bionano Genomics

An institutional investor recently raised its stake in Bionano Genomics stock. Renaissance Technologies LLC raised its stake in Bionano Genomics, Inc. (NASDAQ:BNGO) by 31.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 48,700 shares of the company’s stock after acquiring an additional 11,700 shares during the period. Renaissance Technologies LLC owned approximately 0.44% of Bionano Genomics worth $57,000 as of its most recent SEC filing. Institutional investors own 11.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Weiss Ratings raised shares of Bionano Genomics from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, September 2nd. Wall Street Zen upgraded shares of Bionano Genomics to a “hold” rating in a research report on Saturday, September 26th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Bionano Genomics presently has a consensus rating of “Hold” and a consensus price target of $6.00.

About Bionano Genomics

Bionano Genomics, Inc is a life sciences company that develops genomic analysis solutions based on optical genome mapping (OGM). Its technology is designed to identify structural variations and other genomic abnormalities that may be difficult to detect with traditional sequencing and cytogenetic methods.

The company’s principal platform is the Saphyr system, which includes instrumentation, consumables and software for analyzing ultra-long DNA molecules. Bionano also provides data-analysis tools and informatics solutions intended to support research and clinical workflows in areas such as constitutional genetics, oncology and hematologic malignancies.

Bionano Genomics serves academic, government, pharmaceutical and biotechnology researchers, as well as clinical laboratories in the United States and international markets.